Skip to main content
Harbin Pharmaceutical Group Co.,Ltd. logo

Harbin Pharmaceutical Group Co.,Ltd. — Investor Relations & Filings

Ticker · 600664 ISIN · CNE0000009T3 LEI · 300300G0L086UJ23MI26 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,824 across all filing types
Latest filing 2022-12-06 Governance Information
Country CN China
Listing Shanghai Stock Exchange 600664

About Harbin Pharmaceutical Group Co.,Ltd.

https://www.hayao.com/

Harbin Pharmaceutical Group Co., Ltd. specializes in the research, development, manufacture, and distribution of a diverse range of pharmaceutical and healthcare products. The company's portfolio includes antibiotics, over-the-counter (OTC) medicines, health supplements, traditional Chinese medicines, and animal health products. It operates through several specialized subsidiaries and maintains a significant presence in the production of penicillins and cephalosporins. A key strategic focus involves the health and nutrition sector, bolstered by the acquisition of global nutrition brand GNC. The company leverages large-scale manufacturing capabilities and an extensive distribution network to serve both domestic and international markets. Its operations emphasize technological innovation and quality control across its integrated supply chain, from raw material production to finished dosage forms.

Recent filings

Filing Released Lang Actions
哈药集团股份有限公司董事会战略决策委员会工作细则（2022年12月）
Governance Information Classification · 95% confidence The document is titled as the "Board of Directors Strategic Decision Committee Work Rules" of 哈药集团股份有限公司 (Harbin Pharmaceutical Group Co., Ltd.). It details the establishment, composition, responsibilities, decision-making procedures, meeting rules, and other governance-related aspects of the Board's Strategic Decision Committee. There is no financial data, no mention of financial results, no shareholder voting results, no legal proceedings, no capital changes, and no report publication announcements. The content focuses on internal governance structure and committee rules, which aligns with governance information. The document length is 2025 characters, which is relatively short but contains substantive governance content, not just an announcement or certification. Therefore, the best fitting category is Governance Information (CGR).
2022-12-06 Chinese
哈药集团股份有限公司股东大会议事规则（2022年12月）
Governance Information Classification · 95% confidence The document is titled as "股东大会议事规则" which translates to "Rules of Procedure for the Shareholders' General Meeting" of 哈药集团股份有限公司. It details the rules, procedures, and regulations governing the conduct, organization, and decision-making processes of the shareholders' meetings, including annual and extraordinary general meetings. It does not contain financial statements, audit opinions, or earnings data. It is not a report of results or a notice of voting outcomes but rather a governance document outlining internal rules for shareholder meetings. Therefore, it fits best under Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices.
2022-12-06 Chinese
哈药集团股份有限公司九届十六次监事会决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of a resolution passed by the Supervisory Board of 哈药集团股份有限公司 (Harbin Pharmaceutical Group Co., Ltd.). It details the meeting date, attendance, voting results, and the approval of amendments to the Supervisory Board's rules. It references compliance with various laws and stock exchange regulations and states that the proposal will be submitted to the shareholders' meeting for approval. The document is short (592 characters) and serves as an official announcement of a board/management decision rather than a full report or financial statement. It does not contain financial data or detailed management discussion. Therefore, it fits best under Board/Management Information (MANG).
2022-12-06 Chinese
哈药集团股份有限公司关于政府征收部分房屋资产的公告
Regulatory Filings Classification · 95% confidence The document is an announcement by 哈药集团股份有限公司 regarding the government's expropriation of certain house assets owned by its subsidiary. It details the compensation amount, the impact on the company's profit and loss, and the nature of the transaction. The document is relatively short (1132 characters) and serves as a formal disclosure of a specific transaction rather than a full financial report or audit. It does not contain comprehensive financial statements or detailed financial analysis. This fits the category of a Regulatory Filing (RNS), which covers general regulatory announcements and compliance disclosures that do not fit other specific categories.
2022-12-06 Chinese
哈药集团股份有限公司董事会议事规则（2022年12月）
Governance Information Classification · 95% confidence The document is titled '哈药集团股份有限公司董事会议事规则' which translates to 'Rules of Procedure for the Board of Directors of Harbin Pharmaceutical Group Co., Ltd.' It details the governance structure, meeting procedures, decision-making powers, voting rules, and responsibilities of the board of directors. It references relevant laws and regulations such as the Company Law, Securities Law, and listing rules. The content is focused on internal governance rules and board management rather than financial results, audit, or shareholder meeting materials. It is not a report of financial performance or an announcement but a governance document outlining board procedures and rules. Therefore, it fits the category of Governance Information (CGR). The document length (5612 characters) supports it being a full governance report rather than a brief announcement.
2022-12-06 Chinese
哈药集团股份有限公司外部信息使用人管理制度（2022年12月）
Governance Information Classification · 95% confidence The document is titled '外部信息使用人管理制度' which translates to 'External Information User Management System' and outlines the company's internal policies and procedures for managing the disclosure and use of sensitive company information, including insider information. It references relevant laws and regulations such as the Company Law, Securities Law, and Information Disclosure Management Measures. The content focuses on governance, confidentiality obligations, procedures for external information disclosure, and responsibilities of company personnel and external users. There are no financial statements, earnings data, or report disclosures present. The document is a policy or governance document related to information disclosure management rather than a financial report or announcement. Therefore, the most appropriate classification is Governance Information (CGR). The document length is 2737 characters, which is relatively short and consistent with a governance policy document rather than a full report.
2022-12-06 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.